Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

NCT01739764 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01739764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01739764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
February 19, 2013
Completion date
February 17, 2020
Enrollment
215 (actual)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms